Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIMI Regulatory News (IMI)

Share Price Information for IMI (IMI)

Share Price is delayed by 15 minutes
Get Live Data
2,828.00    0.00 (0.00%)
Bid:
2,170.00
Ask:
3,000.00
Spread: 830.00 (38.249%)
Market Cap: £6.73b
IMI Live PriceLast checked at - London Stock Exchange

Intraday IMI Share Chart

Trading Update

7 Nov 2024 07:00

RNS Number : 2337L
IMI PLC
07 November 2024
 

7 November 2024

 

Resilient quarterly sales with continued margin improvement

Full year adjusted EPS guidance reconfirmed

Acquisition of leading sensor technology business

 

IMI plc ("IMI" or the "Group"), the specialist engineering company, issues the following trading update which covers results for the third quarter from 1 July to 30 September 2024.

 

Roy Twite, Chief Executive, commented:

 

"We continue to expect good organic growth in 2024, having delivered a resilient performance in the third quarter. Organic revenue was up 1%, with good growth in our Automation platform partly offset by a weaker performance in Life Technology, as expected. Process Automation, our largest business sector, had another excellent quarter with continued momentum across our energy end markets and strong order intake.

 

Margins in both platforms were higher in the quarter, benefitting from our significant aftermarket exposure, continued delivery of high value-added solutions for our customers and further efficiency gains.

 

We are reconfirming guidance. We continue to expect that full year adjusted basic earnings per share will be between 120p - 126p, despite seeing some additional foreign exchange headwinds. This guidance represents another year of around 10% adjusted organic operating profit growth."

 

Resilient third quarter performance

 

Third quarter organic revenue was 1% higher than the same period last year, with the Group now 3% higher year to date. Statutory revenue in the quarter was 3% lower than last year, reflecting the foreign currency movements seen in the period.

 

Our complexity reduction initiatives remain on track to deliver £15m of incremental benefits for the full year and £7m in 2025. The programme will complete this year, although IMI will continue identify and execute efficiencies within its operations. Future restructuring costs within our current business will be taken into underlying operating profit.

 

Sector performance in line with expectations

 

Automation

 

Automation (62% of 2023 sales) delivered a strong performance, with revenue in the quarter up 4% organically, and 7% year to date.

 

· Process Automation (37% of 2023 sales) had another excellent quarter as we saw continued momentum across our energy end markets and further progress in the Aftermarket. Order intake in the third quarter was 14% higher organically and revenue was 9% higher than the same period last year on an organic basis. Book-to-bill is now at 1.15 over the last twelve months.

 

· Industrial Automation (25% of 2023 sales) third quarter organic revenue was 2% lower than the same period last year, a resilient performance despite mixed end markets.

 

Life Technology

 

As expected, Life Technology (38% of 2023 sales) revenue was down 5% organically in the third quarter, and 2% lower year to date.

 

· Climate Control (18% of 2023 sales) organic revenue in the third quarter was 4% higher than the same period last year as we saw continued good demand for our energy efficient products.

 

· Life Science and Fluid Control (12% of 2023 sales) organic revenue was down 10% in the third quarter reflecting the continued softness seen across the global life sciences device market.

 

· Transport (8% of 2023 sales) organic revenue was down 16% in the third quarter, as expected given the 20% organic growth delivered in the third quarter of 2023. Sector revenue is now 3% higher year to date.

 

Disciplined approach to capital allocation

 

IMI is a highly cash generative business with a clear and disciplined approach to capital allocation, prioritising investment that accelerates organic growth.

 

IMI will also pursue strategic acquisitions that strengthen its position in attractive, better world markets and deliver returns in line with its strict financial criteria. On 31 October 2024 IMI announced the acquisition of TWTG Group B.V. ("TWTG") for an enterprise value of €25m. TWTG is a leading innovator of smart connected asset monitoring solutions. The combination with IMI will create a significant opportunity to accelerate aftermarket growth in Process Automation.

 

In addition, reflecting its commitment to maintain an efficient balance sheet, IMI announced a £100m share buyback at the interim results in July 2024. The buyback was completed in October.

 

By deploying our growing free cash flow into organic growth opportunities, attractive acquisitions and share buybacks, IMI can continue its track record of compounding EPS growth.

 

Exchange rates

 

If exchange rates as at 1 November 2024 of US$1.29 and €1.19 remain constant for the remainder of the year it would negatively impact both revenue and adjusted operating profit by approximately 3% in the 2024 full year when compared to 2023.

 

Outlook

 

Based on current market conditions, we are reiterating our guidance that 2024 full year adjusted basic EPS will be between 120p - 126p.

 

Interim results

 

IMI will present its preliminary results announcement for the year ending 31 December 2024 on 28 February 2025.

 

Enquiries

 

Edward Hann

IMI

Tel: +44 (0)7977 354 810

Matt Denham

Headland

Tel: +44 (0)7551 825 496

 

A conference call for analysts and investors will be held at 08:00 GMT today to discuss this statement. To access the call, please register using the link:

 

https://www.netroadshow.com/events/login?show=7c005d8a&confId=72097

 

Notes

 

IMI plc is a FTSE100 global specialist engineering company that designs, manufactures and services highly engineered products to control the precise movement of fluids. Its innovative motion and flow control technologies, built around valves and actuators, enable vital sectors to become safer, more sustainable and more productive. IMI combines world class applications engineering expertise with a continued focus on customer satisfaction, market-led innovation and complexity reduction to solve its customers most acute engineering problems. IMI employs approximately 10,000 people, has manufacturing facilities in 18 countries and operates a global service network. The Company is listed on the London Stock Exchange. Further information is available at www.imiplc.com.

 

References to adjusted figures reflect figures as reported to management and do not include the impact of adjusting items. References to organic changes are on a constant currency basis and exclude disposals and acquisitions.

 

IMI plc is registered in England No. 714275. Its legal entity identifier ('LEI') number is 2138002W9Q21PF751R30.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUNSNRSWUARAA
Date   Source Headline
10th Jan 20241:01 pmRNSDirector/PDMR Shareholding
2nd Jan 202411:35 amRNSBlock listing Interim Review
2nd Jan 202411:04 amRNSTotal Voting Rights
19th Dec 20239:55 amRNSDirector/PDMR Shareholding
13th Dec 20233:41 pmRNSDirector/PDMR Shareholding
5th Dec 20239:28 amRNSDirector Declaration
1st Dec 20231:30 pmRNSTotal Voting Rights
15th Nov 20231:42 pmRNSDirector/PDMR Shareholding
9th Nov 20237:01 amRNSHistorical Financial Information
9th Nov 20237:00 amRNSInterim Management Statement
1st Nov 202312:42 pmRNSTotal Voting Rights
11th Oct 20233:20 pmRNSDirector/PDMR Shareholding
2nd Oct 20231:19 pmRNSTotal Voting Rights
13th Sep 20233:32 pmRNSDirector/PDMR Shareholding
1st Sep 202311:29 amRNSTotal Voting Rights
10th Aug 20234:53 pmRNSDirector/PDMR Shareholding
10th Aug 20234:38 pmRNSDirector/PDMR Shareholding
9th Aug 20232:34 pmRNSDirector/PDMR Shareholding
1st Aug 202310:16 amRNSTotal Voting Rights
31st Jul 20231:52 pmRNSDirector/PDMR Shareholding
28th Jul 20237:00 amRNSInterim Results
12th Jul 20231:13 pmRNSDirector/PDMR Shareholding
3rd Jul 20232:58 pmRNSBlock listing Interim Review
3rd Jul 20232:41 pmRNSTotal Voting Rights
26th Jun 20234:39 pmRNSHolding(s) in Company
14th Jun 202310:48 amRNSDirector/PDMR Shareholding
8th Jun 20233:18 pmRNSDirector/PDMR Shareholding
1st Jun 20231:51 pmRNSTotal Voting Rights
22nd May 202310:18 amRNSDirectorate Change
11th May 202311:49 amRNSHolding(s) in Company
10th May 20232:40 pmRNSDirector/PDMR Shareholding
4th May 20231:05 pmRNSResult of AGM
4th May 20237:00 amRNSInterim Management Statement
2nd May 20232:46 pmRNSTotal Voting Rights
14th Apr 20233:18 pmRNSDirector/PDMR Shareholding
12th Apr 202311:29 amRNSDirector/PDMR Shareholding
3rd Apr 202311:38 amRNSTotal Voting Rights
29th Mar 20234:53 pmRNSHolding(s) in Company
27th Mar 202311:35 amRNSDirector/PDMR Shareholding
27th Mar 202311:25 amRNSDirector/PDMR Shareholding
24th Mar 20239:49 amRNSAnnual Financial Report
16th Mar 20239:28 amRNSHolding(s) in Company
15th Mar 20232:13 pmRNSDirector/PDMR Shareholding
8th Mar 20233:19 pmRNSDirector/PDMR Shareholding
3rd Mar 20237:00 amRNSPreliminary Results
1st Mar 20231:36 pmRNSTotal Voting Rights
15th Feb 202312:43 pmRNSDirector/PDMR Shareholding
1st Feb 202312:39 pmRNSTotal Voting Rights
26th Jan 202311:00 amRNSHolding(s) in Company
19th Jan 202310:07 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.